SCHEMBL13698483

SCHEMBL13698483

Cc1ccc(C)c(N2CCN(C3CCC4CCC3C4)CC2)c1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 2/20 0.60
GAA P10253 1/20 0.46
ALOX12 P18054 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
TSHR P16473 2/20 0.43
MAPT P10636 2/20 0.42
ALDH1A1 P00352 2/20 0.42
HTT P42858 1/20 0.42
LMNA P02545 2/20 0.41
USP2 O75604 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13698419 0.92 SLC18A3 (0.60) SLC18A3GAAALOX12SMN1; SMN2MEN1
SCHEMBL13698480 0.83 SLC18A3 (0.58) SLC18A3SMN1; SMN2KMT2ATSHRALDH1A1
SCHEMBL13698511 0.79 NPSR1 (0.51) SLC18A3GAASMN1; SMN2MEN1KMT2A
SCHEMBL13698488 0.79 SLC18A3 (0.57) SLC18A3GAAALOX12SMN1; SMN2MEN1
SCHEMBL13698433 0.79 SLC18A3 (0.53) SLC18A3GAAALOX12SMN1; SMN2MEN1
SCHEMBL13698526 0.77 KMT2A (0.46) SLC18A3SMN1; SMN2MEN1KMT2ATSHR
SCHEMBL15763880 0.76 KMT2A (0.47) SLC18A3GAASMN1; SMN2MEN1KMT2A
SCHEMBL3980241 0.75 SLC18A3 (0.58) SLC18A3SMN1; SMN2MEN1KMT2ATSHR
SCHEMBL13698502 0.73 DRD2 (0.43) SLC18A3GAAKMT2AMAPTALDH1A1
SCHEMBL13698463 0.73 SLC18A3 (0.68) SLC18A3GAAALOX12SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239873-A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors BLANCO MIGUEL GARCIA-GUZMAN 2009-09-24 US disclosed
US-20090239873-A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors BLANCO MIGUEL GARCIA-GUZMAN 2009-09-24 US disclosed
US-7563795-B2 Phenyl-piperazine derivatives as modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-07-21 US disclosed
US-7563795-B2 Phenyl-piperazine derivatives as modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239873-A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 SLC18A3 187/4885GAA 3977/4885ALOX12 2493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.